Cell Biotech Participate in 'HNC 2025' in China - Leading the Globalization of K-Probiotics

Cell Biotech is participating in ‘HNC 2025 (Healthplex Expo 2025)’ held in Shanghai, China. With an independent booth at China’s largest health supplement exhibition, the company is taking a significant step toward the globalization of K-Probiotics.

Marking its 15th edition this year, HNC 2025 is being held over three days from June 24 to 26 at the National Exhibition and Convention Center (NECC) in Shanghai. The event spans approximately 200,000 square meters and is expected to host over 2,500 companies from around the world, attracting more than 120,000 visitors. The expo will showcase the latest technologies and trends across the entire health supplement industry — from raw material supply and finished product manufacturing to global distribution and research institutions.

Cell Biotech, which has ranked No. 1 in probiotic exports for 12 consecutive years, is accelerating its entry into the Chinese market with its flagship K-probiotic brand, ‘DUOLAC.’ At this expo, aligned with the global health trend of ‘Lifelong Health,’ the company plans to showcase ‘DUOLAC Brain Guard’ and ‘DUOLAC Woman Probiotics’ as its core products while exploring various business opportunities.

DUOLAC Brain Guard is a product that has proven the cognitive function improvement effects of CBT probiotics through clinical trials conducted on individuals suspected of mild cognitive impairment (MCI) with an average age of 68.9 years. This product was first unveiled at ‘Vitafoods Europe 2025’ held in Barcelona, Spain, last May, where it attracted significant attention.

At the expo, various seminars and forums will also be held, featuring academic discussions on the future of the health supplement industry and human health. Cell Biotech will present clinical results on the application of probiotics, focusing on the innovation of probiotic use. The company will share findings from CBT probiotic studies on chronic kidney disease (CKD) and pet weight management. The research demonstrated improvements in glomerular filtration rate (GFR) and reductions in uremic toxins and inflammation levels in CKD patients. Additionally, a study involving 41 dogs showed an average weight reduction of 5.26%.

A representative from Cell Biotech said, “Having proven the excellence of Korean probiotics in the global market, Cell Biotech is actively leading efforts to globalize K-Probiotics by securing a strong foothold in the Chinese market, which accounts for about 14% of the global health supplement market.

Through this expo, we plan to expand various export channels, including both business-to-business (B2B) and business-to-consumer (B2C) opportunities.”

Meanwhile, Cell Biotech possesses world-class probiotic development technology and manufacturing expertise, exemplified by its ongoing clinical trials of PP-P8, an innovative colorectal cancer drug based on CBT probiotics. Leveraging this advanced technology, DUOLAC offers customized probiotic strains tailored to different life stages — from newborns to middle-aged adults — providing probiotic solutions that support the health of not only Koreans but people worldwide.